The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

MLA

Soumerai, Jacob D., et al. “The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 23, no. 15, Aug. 2017, pp. 4119–26. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-16-3068.

APA

Soumerai, J. D., Zelenetz, A. D., Moskowitz, C. H., Palomba, M. L., Hamlin, P. A., Jr, Noy, A., Straus, D. J., Moskowitz, A. J., Younes, A., Matasar, M. J., Horwitz, S. M., Portlock, C. S., Konner, J. A., Gounder, M. M., Hyman, D. M., Voss, M. H., Fury, M. G., Gajria, D., Carvajal, R. D., … Gerecitano, J. F. (2017). The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(15), 4119–4126. https://doi.org/10.1158/1078-0432.CCR-16-3068

Chicago

Soumerai, Jacob D, Andrew D Zelenetz, Craig H Moskowitz, M Lia Palomba, Paul A Hamlin Jr, Ariela Noy, David J Straus, et al. 2017. “The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 23 (15): 4119–26. doi:10.1158/1078-0432.CCR-16-3068.